Yes, Alnylam has had some bad news. But the bad news isn't as horrible as many think.

The S&P 500 is now sitting just below its record high, with another strong earnings season helping stocks remain near their highs. The strength has not been limited to just a handful of companies either, with most S&P 500 sectors contributing to earnings growth during the current reporting season.Summer Sale - Claim 70% Off TipRanks Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and disco

Why treatments from Alnylam, Merck, AbbVie and Roche stumbled in the last quarter.

Investors need to pay close attention to ALNY stock based on the movements in the options market lately.

TTR franchise revenues topped $1 billion for first time as AMVUTTRA gains traction.

Starbucks upgraded, eBay downgraded: Wall Street's top analyst calls

The biotech's shares have stumbled after a guidance change, and investors are weighing whether this is the moment to step in or step aside.

Alnylam stock plunges after Q2 earnings and revenue miss estimates, while a cut to 2026 product sales guidance overshadows record quarterly Amvuttra sales.

The Morning Bull - US Market Morning Update Friday, Jul, 31 2026 US stock futures are pointing higher this morning, with E-mini S&P 500 contracts up about 0.3% and Nasdaq-100 futures ahead roughly 0.5%. The focus is on the June US PCE price index, which is expected to dip 0.1% month on month, while the core reading is seen up 0.2%. That combination suggests the cost of living may be easing slowly but still sits above the Federal Reserve's 2% goal. At the same time, second quarter US GDP is...

TTR franchise revenues topped $1 billion for first time as AMVUTTRA gains traction.